Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment
After months of confronting COVID-19 pandemic, several countries, including Saudi Arabia, have recently approved newly developed vaccines to prevent COVID-19 infection. With the new technology utilized to develop some vaccines, questions arise about their long-term safety. To provide rapid response...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2021-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_3d75b35b58654fc7b6866f0b6dbd86b3 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yasser Albogami |e author |
| 700 | 1 | 0 | |a Hadeel Alkofide |e author |
| 700 | 1 | 0 | |a Adel Alrwisan |e author |
| 245 | 0 | 0 | |a Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment |
| 260 | |b Elsevier, |c 2021-08-01T00:00:00Z. | ||
| 500 | |a 1319-0164 | ||
| 500 | |a 10.1016/j.jsps.2021.07.005 | ||
| 520 | |a After months of confronting COVID-19 pandemic, several countries, including Saudi Arabia, have recently approved newly developed vaccines to prevent COVID-19 infection. With the new technology utilized to develop some vaccines, questions arise about their long-term safety. To provide rapid response to emerging safety issues, robust surveillance programs that provide near real-time analysis of vaccines effects are required. Saudi Arabia has a well-established passive pharmacovigilance system that monitors drugs and vaccines safety. However, recent development in health digitalization in Saudi Arabia may provide a unique opportunity to harvest existing resources to generate high-quality evidence. This commentary provides an overview of the available systems that can be utilized to monitor the COVID-19 vaccines' safety and discusses opportunities for data integration to improve data quality and generate real-world evidence on COVID-19 vaccine safety. | ||
| 546 | |a EN | ||
| 690 | |a Real-world data | ||
| 690 | |a COVID-19 vaccine | ||
| 690 | |a Active surveillance | ||
| 690 | |a Pharmacovigilance | ||
| 690 | |a Pharmacoepidemiology | ||
| 690 | |a Saudi Arabia | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Saudi Pharmaceutical Journal, Vol 29, Iss 8, Pp 914-916 (2021) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1319016421001328 | |
| 787 | 0 | |n https://doaj.org/toc/1319-0164 | |
| 856 | 4 | 1 | |u https://doaj.org/article/3d75b35b58654fc7b6866f0b6dbd86b3 |z Connect to this object online. |